65,437 trials
Arterial Hypertension · Hypertension, Resistant to Conventional Therapy · Diabetes Mellitus
Primary: Change of of Systolic Blood Pressure — -9.6; -0.7 mm Hg
Postoperative Pain
Primary: QoR40 on the Day After Surgery — 152; 180; 180 units on a scale — p=.05
Chronic Hepatitis C
Primary: Percentage of Participants Achieving Sustained Virologic Response (SVR)12 — 91 percentage of participants — p=< 0.001
Immune Thrombocytopenic Purpura
Primary: Percentage of Participants With a Clinical Response — 80.0 Percentage of participants
Type 2 Diabetes Mellitus
Primary: Change From Baseline in HbA1c at Week 12 — 0.29; -0.71 percentage of HbA1c
Meningococcal Disease · Meningitis
Primary: Number of Participants With Seroconversion Following Vaccination With Either Sanofi Pasteur Meningococcal A+C Polysaccharide Vaccine or Lanzhou Institute of Biological…
Rheumatoid Arthritis
Primary: Percentages of Patients With Treatment-emergent or Serious Adverse Events — 54.2; 63.6; 65.2; 60.9 percentage of participants
Smoking Cessation
Primary: Percentage of Change in Expired Air Carbon Monoxide (CO) at End of Week 1 — 1.73; -14.11; -.63 percentage change
Inflammatory Bowel Disease
Primary: PDK4 mRNA — .776; 1.30 copies/nL — p=.01
HIV Infections
Primary: Trough Cpre,N. — 15.47; 16.66 (ng/mL/mg) — p=0.0080
Diabetic Macular Edema
Primary: Visual Acuity — 18.9; 28.7; 27.8 percentage of subjects
Emergence Agitation
Primary: The Incidence of Emergence Agitation Using Four-point Categorical Scale — 51; 17 participants
Psoriasis
Primary: Percentage of Participants With a Physician's Global Assessment (PGA) Response of "Clear" or "Almost Clear" at Week 12 — 47.11; 68.18; 66.27; 14.95 percentage of…
Lymphoma
Primary: 12-Month Progression-Free Survival (PFS) — 0.44 probability
Deep Extubation
Primary: Awakening Time — 10; 7 minutes